Literature DB >> 17664052

Nurse practitioner and physician assistant interest in prescribing buprenorphine.

Robert J Roose1, Hillary V Kunins, Nancy L Sohler, Rashiah T Elam, Chinazo O Cunningham.   

Abstract

Office-based buprenorphine places health care providers in a unique position to combine HIV and drug treatment in the primary care setting. However, federal legislation restricts nurse practitioners (NPs) and physician assistants (PAs) from prescribing buprenorphine, which may limit its potential for uptake and inhibit the role of these nonphysician providers in delivering drug addiction treatment to patients with HIV. This study aimed to examine the level of interest in prescribing buprenorphine among nonphysician providers. We anonymously surveyed providers attending HIV educational conferences in six large U.S. cities about their interest in prescribing buprenorphine. Overall, 48.6% (n = 92) of nonphysician providers were interested in prescribing buprenorphine. Compared to infectious disease specialists, nonphysician providers (adjusted odds ratio [AOR] = 2.89, 95% confidence interval [CI] = 1.22-6.83) and generalist physicians (AOR = 2.04, 95% CI = 1.09-3.84) were significantly more likely to be interested in prescribing buprenorphine. NPs and PAs are interested in prescribing buprenorphine. To improve uptake of buprenorphine in HIV settings, the implications of permitting nonphysician providers to prescribe buprenorphine should be further explored.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17664052      PMCID: PMC2486415          DOI: 10.1016/j.jsat.2007.05.009

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  13 in total

1.  Professional satisfaction experienced when caring for substance-abusing patients: faculty and resident physician perspectives.

Authors:  Richard Saitz; Peter D Friedmann; Lisa M Sullivan; Michael R Winter; Christine Lloyd-Travaglini; Mark A Moskowitz; Jeffrey H Samet
Journal:  J Gen Intern Med       Date:  2002-05       Impact factor: 5.128

2.  Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence.

Authors:  Barbara J Turner; Christine Laine; Yi-Ting Lin; Kevin Lynch
Journal:  Arch Intern Med       Date:  2005 Aug 8-22

3.  The substance abuse attitude survey: an instrument for measuring attitudes.

Authors:  J N Chappel; T L Veach; R S Krug
Journal:  J Stud Alcohol       Date:  1985-01

4.  Quality of HIV care provided by nurse practitioners, physician assistants, and physicians.

Authors:  Ira B Wilson; Bruce E Landon; Lisa R Hirschhorn; Keith McInnes; Lin Ding; Peter V Marsden; Paul D Cleary
Journal:  Ann Intern Med       Date:  2005-11-15       Impact factor: 25.391

5.  Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States.

Authors:  E G Bing; M A Burnam; D Longshore; J A Fleishman; C D Sherbourne; A S London; B J Turner; F Eggan; R Beckman; B Vitiello; S C Morton; M Orlando; S A Bozzette; L Ortiz-Barron; M Shapiro
Journal:  Arch Gen Psychiatry       Date:  2001-08

Review 6.  The potential role of buprenorphine in the treatment of opioid dependence in HIV-infected individuals and in HIV infection prevention.

Authors:  Frederick L Altice; Lynn E Sullivan; Duncan Smith-Rohrberg; Sanjay Basu; Sharon Stancliff; Lois Eldred
Journal:  Clin Infect Dis       Date:  2006-12-15       Impact factor: 9.079

Review 7.  Buprenorphine: its role in preventing HIV transmission and improving the care of HIV-infected patients with opioid dependence.

Authors:  Lynn E Sullivan; David A Fiellin
Journal:  Clin Infect Dis       Date:  2005-08-10       Impact factor: 9.079

8.  HIV diagnoses among injection-drug users in states with HIV surveillance--25 states, 1994-2000.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2003-07-11       Impact factor: 17.586

9.  Effects of a quality improvement collaborative on the outcome of care of patients with HIV infection: the EQHIV study.

Authors:  Bruce E Landon; Ira B Wilson; Keith McInnes; Mary Beth Landrum; Lisa Hirschhorn; Peter V Marsden; David Gustafson; Paul D Cleary
Journal:  Ann Intern Med       Date:  2004-06-01       Impact factor: 25.391

10.  Specialty training and specialization among physicians who treat HIV/AIDS in the United States.

Authors:  Bruce E Landon; Ira B Wilson; Neil S Wenger; Susan E Cohn; Carl J Fichtenbaum; Samuel A Bozzette; Martin F Shapiro; Paul D Cleary
Journal:  J Gen Intern Med       Date:  2002-01       Impact factor: 5.128

View more
  5 in total

1.  A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder.

Authors:  Katharine Cioe; Breanne E Biondi; Rebecca Easly; Amanda Simard; Xiao Zheng; Sandra A Springer
Journal:  J Subst Abuse Treat       Date:  2020-09-22

2.  HIV provider endorsement of primary care buprenorphine treatment: a vignette study.

Authors:  Hillary V Kunins; Nancy L Sohler; Robert J Roose; Chinazo O Cunningham
Journal:  Fam Med       Date:  2009 Nov-Dec       Impact factor: 1.756

Review 3.  Research on the diffusion of evidence-based treatments within substance abuse treatment: a systematic review.

Authors:  Bryan R Garner
Journal:  J Subst Abuse Treat       Date:  2008-11-12

4.  Beyond state scope of practice laws for advanced practitioners: Additional supervision requirements for buprenorphine prescribing.

Authors:  Barbara Andraka-Christou; Adam J Gordon; Joanne Spetz; Rachel Totaram; Matthew Golan; Olivia Randall-Kosich; Jordan Harrison; Spencer Calder; Stefan G Kertesz; Bradley D Stein
Journal:  J Subst Abuse Treat       Date:  2022-01-10

5.  Toward cost-effective staffing mixes for Veterans Affairs substance use disorder treatment programs.

Authors:  Jinwoo J Im; Ross D Shachter; John W Finney; Jodie A Trafton
Journal:  BMC Health Serv Res       Date:  2015-11-23       Impact factor: 2.655

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.